All products / DC8127
KRCA-0008
Pack sizes and prices
| Pack size | Price |
|---|---|
| 100 mg | $500 USDRequest a quote → |
| 250 mg | $900 USDRequest a quote → |
| 1 g | $1,900 USDRequest a quote → |
In stock. Contact our team for lead time, shipping and final quotation.
Product overview
KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.IC50 value: 12 nM/4 nM(ALK/Ack1) [1]Target: ALK/Ack1 inhibitorKRCA-0008 retains good drug-like properties: good water-solubility (54 μM in 5% DMSO–water, 150 μM in 5% DMSO–PBS buffer) with moderate plasma protein binding (93% in rat) and low brain exposure (Cbrain/Cplasma = ~0.02). It has good liver microsomal stability (% remaining after 30 min: 52% in mouse, 89% in rat, 72% in human) and little to no CYP inhibition (1A2, 2C9, 2D6, 3A4 @ 10 μM). It does not appear to cause hERG blockade (patch clamp IC50 = 30 μM) and is negative on Ames test (1000 μg/plate), chromosomal aberration assay and micronucleus assay.KRCA-0008 also shows promising pharmacokinetic parameters in both mice and rat (oral bioavailability = 66–94.5%). KRCA-0008 shows a modest tumor growth inhibition in vivo activity in H3122 human lung cancer bearing mice model comparable to Crizotinib without significant body weight change. It is important to mention the KRCA-0008 25 mpk and 50 mpk groups did not show dose-dependent tumor growth inhibition.
For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.
Identity and specifications
| Catalog number | DC8127 |
|---|---|
| Product name | KRCA-0008 |
| CAS | 1472795-20-2 |
| Molecular formula | C30N8O4ClH37 |
| Molecular weight | 609.119 |
| Purity | >98% |
| SMILES | ClC1=C([H])N=C(N=C1N([H])C1C([H])=C([H])C(=C([H])C=1OC([H])([H])[H])N1C([H])([H])C([H])([H])N(C(C([H])([H])[H])=O)C([H])([H])C1([H])[H])N([H])C1C([H])=C([H])C(=C([H])C=1OC([H])([H])[H])N1C([H])([H])C([H])([H])N(C(C([H])([H])[H])=O)C([H])([H])C1([H])[H] |
Source-listed specifications; the batch COA applies.
Source and product documents
The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.
DC Chemicals — KRCA-0008 (DC8127)Source references
[1]. Park CH, et al. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Bioorg Med Chem Lett. 2013 Nov 15;23(22):6192-6.
